Clinical trial
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
NCT06373913 is registered in ClinicalTrials.gov with Kolding Sygehus as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
- Lead sponsor
- Kolding Sygehus
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- June 1, 2023
- Completion date
- July 30, 2028
- Enrollment
- 75 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.